Please login to the form below

Not currently logged in
Email:
Password:

Glenmark settles with Astellas/ Triax

Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin

India-based generics manufacturer Glenmark has settled a US patent infringement suit with Triax Pharmaceuticals and Astellas over a generic version of a cream for inflammation of the skin.

The suit relates to an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) for a form of hydrocortisone butyrate cream, Glenmark's generic equivalent of Locoid Lipocream, currently registered by Astellas and licensed to Triax.

Under the settlement and licence agreement, Glenmark will be permitted to market and distribute its version of the cream under a royalty-bearing licence from Astellas and Triax in the US by the end of 2013.

In a statement, Glenmark said it believed it was entitled to 180 days of exclusivity to market the product as the first generic company to file a related ANDA.

According to IMS Health data, Locoid Lipocream had sales of around $38m for 2010.

25th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics